Global Primary Biliary Cholangitis Therapeutics Market 2019-2023

The global primary biliary cholangitis (PBC) therapeutics market size will grow by USD 241.28 million during 2019-2023. The PBC therapeutics market report provides a detailed analysis of the market by product (OCALIVA, Ursodiol, and others) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc., and Takeda Pharmaceutical Co. Ltd.

A few of the key findings from this global primary biliary cholangitis therapeutics market analysis report are summarized below

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the PBC therapeutics market report.

Get a FREE sample now!

Global Primary Biliary Cholangitis Therapeutics Market Overview

There is a dire need for curative therapy for primary biliary cholangitis across the world. This is because of the recurring nature of the disease. Currently, the only cure for the condition is a liver transplant. This method of treatment makes it difficult for patients to lead a normal life even with post-surgery treatment. This has resulted in research on stem cell transplantation to replace destroyed cells in the bile duct. Although research on regenerative therapy is in its nascent stage, this trend will add significant value to the growth of the global primary biliary cholangitis therapeutics market during 2019-2023.

The growing awareness campaigns to reduce further complications in the primary biliary cholangitis indication is one of the key market growth drivers. The asymptomatic nature of the condition causes a delay in diagnosis in most of the cases. Also, the majority of the population is not aware of the symptoms of indications. Many vendors leveraged on this situation and started organizing awareness campaigns. Various non-profit organizations are also running awareness programs and funding research on novel therapies to treat the condition. These factors will increase the sales of primary biliary cholangitis therapeutics and contribute to the growth of the market, which will register a CAGR of close to 10% during the forecast period.

Top Primary Biliary Cholangitis Therapeutics Companies Covered in this Market Research Report

The global primary biliary cholangitis therapeutics market is concentrated. The PBC therapeutics market report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. The will help clients in improving their market positions. It also provides a detailed analysis of the upcoming primary biliary cholangitis therapeutics market trends and challenges that will influence market growth. The research will help companies in creating effective strategies to leverage the upcoming market growth opportunities.

The report offers a detailed analysis of many leading Primary Biliary Cholangitis Therapeutics companies, including:

• Abbott Laboratories
• Allergan Plc
• Eli Lilly and Co.
• Intercept Pharmaceuticals Inc.
• Takeda Pharmaceutical Co. Ltd.

Primary Biliary Cholangitis Therapeutics Market Segmentation Based on Product

• OCALIVA
• Ursodiol
• Others

OCALIVA held the largest market share in 2018. It will maintain its dominance in 2023 as well. OCALIVA was developed to treat various liver-related indications. It is currently the most preferred drug to treat primary biliary cholangitis owing to its strong efficacy to target cells compared with other available drugs in the market.

Primary Biliary Cholangitis Therapeutics Market Segmentation Based on Geographic Region

• APAC
• Europe
• North America
• ROW

North America has a high prevalence of primary biliary cholangitis indication. Therefore, the sales of primary biliary cholangitis therapeutics have been high in the region. These factors rendered the region the highest market shareholder in 2018. The sales of drugs for primary biliary cholangitis indication were the highest in the US. The demand for therapeutics as a treatment option will increase in North America during the forecast period. Such factors will aid the region in maintaining its dominance during the forecast period.

Key Highlights of the Global Primary Biliary Cholangitis Therapeutics Market Forecast Report for the Period 2019-2023

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will accelerate the growth of the primary biliary cholangitis therapeutics market during the next five years
• Precise estimation of the global primary biliary cholangitis therapeutics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the primary biliary cholangitis therapeutics industry across APAC, Europe, North America, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details of factors that will challenge the growth of primary biliary cholangitis therapeutics companies

We can help! Our analysts can customize the PBC therapeutics market research report to meet your requirements. Get in touch